Ke-Wu Zeng on molecular glues for cancer therapy
eBioMedicine in conversation with - A podcast by The Lancet Group
Categorie:
Drs Zeng join eBioMedicine to discuss their study of a novel molecular glue, called bufalin. Read the full article: Atypical E3 ligase ZFP91 promotes small-molecule-induced E2F2 transcription factor degradation for cancer therapy Continue this conversation on social! Follow us today at... https://twitter.com/thelancet https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
